WallStSmart
NCEL

NewcelX Ltd.

NASDAQ: NCEL · HEALTHCARE · BIOTECHNOLOGY

$2.70
-1.46% today

Updated 2026-10-28

Market cap
$14.44M
P/E ratio
4.81
P/S ratio
—
EPS (TTM)
$0.52
Dividend yield
—
52W range
$2 – $17
Volume
0.0M

NewcelX Ltd. (NCEL) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201720182019202020212022202320242025
Operating cash flow$-5.43M$-2.73M$-190009.00$-729386.00$-14.94M$-13.88M$-9.68M$-4.27M$-2.77M
Capital expenditures$0.00$0.00$0.00$4.00$39560.00$640000.00$4.00$3917.00$8000.00
Depreciation—$1.09M—$72.19M$10050.00$11408.00$11408.00$3321.00—
Stock-based comp$77.00———$327000.00$22730.00$164906.00$125644.00$765000.00
Free cash flow$-5.43M$-2.73M$-190009.00$-729390.00$-14.98M$-14.52M$-9.68M$-4.27M$-2.77M
Investing cash flow——$-217252.00$225638.00$-39560.00$-3.51M—$-3917.00—
Financing cash flow$6.73M$557920.00$407479.00$503522.00$20.34M$17.40M$1.63M$5.04M—
Dividends paid—————————
Share repurchases—————————
Debt repayment—————————
Net change in cash—————————

Frequently asked questions

How much free cash flow does NCEL generate?

NCEL produced $-2.77M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NCEL's balance sheet healthy?

NCEL holds $2.20M in cash and equivalents against — in long-term debt, on $7.25M of shareholder equity. That debt is best read against the cash flow the business throws off each year.